Fluoxetine in Pediatric Body Dysmorphic Disorder (FDA BDD)
Sponsor: Food and Drug Administration (FDA)
A PHASE4 clinical study on Body Dysmorphic Disorder, this trial is completed. The trial is conducted by Food and Drug Administration (FDA) and has accumulated 9 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
May 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — May 2018 [monthly]
Completed PHASE4
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Food and Drug Administration (FDA)
- Montefiore Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .